T. Rowe Price Associates
AZN icon

T. Rowe Price Associates’s AstraZeneca AZN Stock Holding History

T. Rowe Price Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,750
Closed -$524K – 2981
2021
Q4 		$524K Sell
4,750
-7,000
-60% -$824K ﹤0.01% 2367
2021
Q3 		$1.41M Buy
11,750
+1,150
+11% +$134K ﹤0.01% 1875
2021
Q2 		$1.27M Buy
+10,600
New +$1.16M ﹤0.01% 1959

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates's AZN Position: Q1 2026 in Review

T. Rowe Price Associates reduced its AstraZeneca (AZN) stake by 20% in Q1 2026, selling an estimated $932M and leaving 19,489,220 shares worth $3.84B. The position accounts for 0.44% of the portfolio, ranked #35.

T. Rowe Price Associates first reported a position in AZN in Q2 2013 and has held it in 43 quarters since. The position peaked at $6.25B in Q1 2022. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • T. Rowe Price Associates held 19,489,220 shares of AstraZeneca worth $3.84B as of Q1 2026.
  • T. Rowe Price Associates sold 4,832,694 AstraZeneca shares in Q1 2026, an estimated $932M.
  • AstraZeneca made up 0.44% of T. Rowe Price Associates's portfolio in Q1 2026, its #35 holding.
  • T. Rowe Price Associates first reported a position in AstraZeneca in Q2 2013 and has held it in 43 quarters since.
  • T. Rowe Price Associates's AstraZeneca position peaked at $6.25B in Q1 2022.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.